Company Overview

Immutep Limited (NASDAQ: IMMP; ASX: IMM) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company’s core scientific platform centers on lymphocyte activation gene-3 (LAG-3), an immune checkpoint molecule involved in regulating T-cell function. Immutep operates within the oncology and immuno-oncology industries, with its primary value drivers tied to the development, licensing, and commercialization potential of LAG-3-based therapeutics. Its lead product candidate, eftilagimod alpha (efti), is designed as a soluble LAG-3 protein that stimulates antigen-presenting cells to enhance immune responses, particularly in combination with checkpoint inhibitors and chemotherapy.

The company traces its origins to research conducted by French immunologist Frédéric Triebel, who discovered LAG-3 and founded the precursor entity that later evolved into Immutep. Over time, Immutep transitioned from a broader immunology platform into a focused immuno-oncology developer with clinical programs targeting solid tumors and hematologic cancers. The company differentiates itself through a substantial intellectual property portfolio surrounding LAG-3 biology and through its positioning as one of the earlier companies to clinically develop both agonist and antagonist applications linked to the LAG-3 pathway.

Business Operations

Immutep generates value primarily through clinical development activities, strategic collaborations, licensing agreements, and potential milestone payments tied to its intellectual property and therapeutic pipeline. Its principal operating focus is the advancement of eftilagimod alpha across multiple oncology indications, including non-small cell lung cancer, breast cancer, and head and neck cancers. The company also maintains programs involving LAG-3 antagonists and depleting antibodies intended to complement broader immunotherapy approaches. Operations are primarily research and development driven, reflecting its status as a pre-commercial biotechnology company.

The company operates internationally, with corporate headquarters in Sydney, Australia, and significant operational and research activities in Europe, particularly France. Immutep controls a broad LAG-3 patent estate and collaborates with major pharmaceutical and biotechnology companies. Partnerships have included collaborations with Merck & Co., Pfizer, and Novartis tied to combination therapy development and licensing arrangements involving LAG-3 technologies. The company has also historically maintained subsidiaries and operating entities in Australia, France, and the United States to support clinical development, regulatory activities, and investor engagement.

Strategic Position & Investments

Immutep’s strategic direction centers on advancing LAG-3-based immunotherapies through combination treatment strategies in oncology. A major component of its growth strategy involves positioning eftilagimod alpha alongside established checkpoint inhibitors such as anti–PD-1 therapies, with the objective of improving response rates and durability in difficult-to-treat cancers. The company has invested heavily in clinical trials evaluating efti in metastatic breast cancer and lung cancer, including studies involving first-line treatment settings where commercial opportunity is substantial.

The company’s broader portfolio includes assets targeting autoimmune diseases and additional oncology applications tied to LAG-3 modulation. Immutep has historically monetized portions of its intellectual property through licensing transactions and collaboration agreements with larger pharmaceutical companies pursuing immune checkpoint therapeutics. Its strategic positioning benefits from the broader industry validation of the LAG-3 pathway following regulatory approvals of LAG-3-targeting drugs developed by other biotechnology and pharmaceutical firms, reinforcing the commercial relevance of the company’s underlying scientific platform.

Geographic Footprint

Immutep maintains a multinational operational structure with headquarters in Sydney, Australia, while much of its scientific and clinical activity is conducted in Europe and the United States. The company’s research heritage and several operational functions remain closely linked to France, where foundational LAG-3 discoveries originated and where portions of its scientific infrastructure have historically been based.

Clinical trials sponsored or supported by Immutep have involved sites across North America, Europe, and the Asia-Pacific region, reflecting the global nature of oncology drug development. Through partnerships and licensing arrangements, the company also maintains indirect commercial and scientific exposure to major pharmaceutical markets worldwide. Its investor base spans both Australian and U.S. capital markets due to its dual ASX and NASDAQ listings.

Leadership & Governance

Immutep’s leadership team combines biotechnology commercialization experience with scientific expertise in immunology and oncology drug development. The company’s governance structure reflects its status as a publicly traded clinical-stage biotechnology company subject to both Australian and U.S. market oversight standards. Leadership strategy has consistently emphasized advancing late-stage clinical development while leveraging partnerships to extend financial and operational capacity.

Key executives and directors include:

• Marc Voigt – Chief Executive Officer
• Frédéric Triebel, M.D., Ph.D. – Chief Scientific Officer
• Jonathan Dodd – Chief Financial Officer
• Nathalie Pauwels – Chief Operating Officer
• Pierre-Henri Benhamou, M.D. – Chairman of the Board

The company’s leadership philosophy has focused on establishing Immutep as a specialist immunotherapy developer built around the clinical and commercial potential of the LAG-3 pathway. Public filings and investor communications consistently emphasize disciplined clinical execution, strategic collaborations, and expansion of the company’s immuno-oncology pipeline.